Type 1 Diabetes
50 views | +0 today
Follow
Type 1 Diabetes
Type 1 diabetes is a life-long autoimmune disease that usually occurs in childhood but can be diagnosed at any age.
Your new post is loading...
Your new post is loading...
Scooped by Catherine Forbes
Scoop.it!

DexCom Proudly Sponsors Historic Diabetes Flight Formation Trip toRaise Juvenile Diabetes Research Foundation Funds

DexCom Proudly Sponsors Historic Diabetes Flight Formation Trip toRaise Juvenile Diabetes Research Foundation Funds | Type 1 Diabetes | Scoop.it
more...
No comment yet.
Scooped by Catherine Forbes
Scoop.it!

Feasibility of Artificial Pancreas System Demonstrated in Real-World ... - Sacramento Bee

Feasibility of Artificial Pancreas System Demonstrated in Real-World ... - Sacramento Bee | Type 1 Diabetes | Scoop.it
Zee NewsFeasibility of Artificial Pancreas System Demonstrated in Real-World ...Sacramento BeeJDRF-funded research demonstrates the feasibility of a wearable artificial pancreas to control blood sugar levels in first outpatient study--Liquid glucagon...
more...
No comment yet.
Rescooped by Catherine Forbes from diabetes and more
Scoop.it!

Kids First, Diabetes Second Book

Kids First, Diabetes Second Book | Type 1 Diabetes | Scoop.it
In the book Kids First, Diabetes Second: tips for parenting a child with type 1 diabetes, Leighann Calentine shares wit, wisdom, and tips for parents raising diabetic children.

Via Ellen H Ullman, MSW
more...
No comment yet.
Rescooped by Catherine Forbes from diabetes and more
Scoop.it!

Dexcom Receives CE Mark Approval for the Dexcom G4® Continuous Glucose Monitoring System | Business Wire

Dexcom Receives CE Mark Approval for the Dexcom G4® Continuous Glucose Monitoring System | Business Wire | Type 1 Diabetes | Scoop.it
Dexcom Receives CE Mark Approval for the Dexcom G4® Continuous Glucose Monitoring System...

Via Ellen H Ullman, MSW
more...
No comment yet.
Scooped by Catherine Forbes
Scoop.it!

JDRF, Novo Nordisk Ink Type 1 Diabetes Partnership as Firm Opens ... - Genetic Engineering News

JDRF, Novo Nordisk Ink Type 1 Diabetes Partnership as Firm Opens ... - Genetic Engineering News | Type 1 Diabetes | Scoop.it
Practice BusinessJDRF, Novo Nordisk Ink Type 1 Diabetes Partnership as Firm Opens ...Genetic Engineering NewsCollaboration aims to speed immunotherapy candidates into exploratory human trials.JDRF, Novo Nordisk tie-up to discover & develop new ...pharmabiz.comJDRF...
more...
No comment yet.
Rescooped by Catherine Forbes from diabetes and more
Scoop.it!

JDRF and Novo Nordisk Establish R&D Collaboration for Type 1 #diabetes

JDRF and Novo Nordisk Establish R&D Collaboration for Type 1 #diabetes | Type 1 Diabetes | Scoop.it

JDRF and Novo Nordisk Establish R&D Collaboration for Type 1 Diabetes
-- Focus Will Be on Disease-Modifying Immunotherapies for Type 1 Diabetes--

Contact:
William Sorensen
wsorensen@jdrf.org
(212) 479-7558

New York, NY and Copenhagen, Denmark, June 13, 2012-To address the underlying autoimmune process that is central to type 1 diabetes (T1D), JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease. Type 1 diabetes occurs when the body's immune system attacks and destroys the glucose-responsive, insulin-secreting beta cells of the pancreas, resulting in a lifetime requirement of insulin replacement therapy.

The collaboration between JDRF and Novo Nordisk will focus on research originating from academia and biotechnology companies, as well as from internal research projects at Novo Nordisk.

"JDRF is deeply committed to developing immunotherapies, and especially auto antigen-specific immunotherapies for the prevention and cure of type 1 diabetes," said Dr. Richard Insel, JDRF's chief scientific officer. "This collaboration with Novo Nordisk affords an exciting opportunity to accelerate the timeframe when these therapies may prove to make an impact in type 1 diabetes."

The collaboration with Novo Nordisk will be run out of the company's newly opened Type 1 Diabetes Research and Development (R&D) Center in Seattle. The center, led by Dr. Matthias von Herrath, plans to employ 20 immunotherapy researchers working in Seattle supported by corporate R&D functions in Princeton, NJ and Denmark. The center's goal is to use translational research methods to rapidly move early-stage discovery projects in immunotherapy from animal models into small clinical exploratory trials in T1D.

"It is not a coincidence that we are opening our new Type 1 Diabetes Research and Development Center in Seattle at that same time that we announce a scientific partnership between our company and JDRF," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. "Our new R&D center is founded on the principle of reaching out to academia, biotechnology companies, and other key players in the international immunotherapy research community in order to join forces to develop the next treatment advance in the management of type 1 diabetes. At Novo Nordisk, our vision is to prevent, treat, and ultimately cure diabetes, and every collaboration down that path brings us closer to that goal."


Via Ellen H Ullman, MSW
more...
No comment yet.